2024
Practice Patterns and Trends in the Surgical Management of Mismatch Repair Deficient Colon Cancer
Gupta P, Zhan P, Leeds I, Mongiu A, Reddy V, Pantel H. Practice Patterns and Trends in the Surgical Management of Mismatch Repair Deficient Colon Cancer. Journal Of Surgical Research 2024, 304: 371-382. PMID: 39615154, DOI: 10.1016/j.jss.2024.10.041.Peer-Reviewed Original ResearchLynch syndromePractice patternsCancers associated with Lynch syndromeColorectal cancerColon cancerNonmetastatic colorectal cancerDiagnosed CRC patientsMismatch repairDetect mismatch repairSurgical managementMMR-DMMR testingCRC patientsSurgical practice patternsAssociated with decreased ratesBlack raceRate of extended resectionDNA mismatch repairMismatch repair-proficient tumorsNational Cancer DatabaseNonmetastatic CRC patientsColon cancer patientsGermline mutationsCancer patientsTreatment decisionsThe effects of a psychoeducational intervention on caregivers of colorectal cancer patients: A meta-analysis of randomized controlled trials
Zhang M, Xue Y, Shao M, Yang Y, Yu L, Ma B, Li D, Zhou H, Wang K, Chen C, Cheng M, Wang T. The effects of a psychoeducational intervention on caregivers of colorectal cancer patients: A meta-analysis of randomized controlled trials. European Journal Of Oncology Nursing 2024, 74: 102739. PMID: 39729814, DOI: 10.1016/j.ejon.2024.102739.Peer-Reviewed Original ResearchConceptsPsychoeducational interventionRandomized Controlled TrialsPsychological statusImpact of psychoeducational interventionsAspects of caregivingReduce caregiver burdenControlled TrialsEnhancing caregivers' abilityCondition of caregiversImprove quality of lifeQuality of lifeCaregiver burdenCRC patientsRandom-effects modelCaregivers' abilityCINAHL CompletePerception of family supportGeneral well-beingActive lifestyleWeb of ScienceMeta-analysis of randomized controlled trialsPhysical healthCare scheduleSocial supportFixed-effects modelAnalysis of Risk Factors, Treatment Patterns, and Survival Outcomes After Emergency Presentation With Colorectal Cancer: A Prospective Multicenter Cohort Study in Nigeria
Aderibigbe A, Dare A, Kalvin H, Olasehinde O, Wuraola F, Adisa A, Omisore A, Komolafe A, Omoyiola O, Okereke C, Katung A, Egberoungbe A, Ariyibi O, Olatoke S, Adeyeye A, Agodirin S, Bojuwoye M, Fayenuwo J, Ademakinwa O, Osinowo D, Lawal A, Abdulkareem F, Goldman D, Knapp G, Murthy S, Kahn R, Gonen M, Kingham T, Alatise O, Group F. Analysis of Risk Factors, Treatment Patterns, and Survival Outcomes After Emergency Presentation With Colorectal Cancer: A Prospective Multicenter Cohort Study in Nigeria. Journal Of Surgical Oncology 2024, 131: 170-182. PMID: 39574208, DOI: 10.1002/jso.27878.Peer-Reviewed Original ResearchEmergency presentationsOverall survivalColorectal cancerCRC patientsCancer control effortsAssociated with worse OSCancer family historyElective patientsEmergency patientsRisk factorsLower household incomeLow educational levelOutcome of colorectal cancerProspective multicenter cohort studyStage IV diseaseSurgery improves survivalConsecutive CRC patientsKaplan-Meier methodLog-rank testMulticenter cohort studyAnalysis of risk factorsAccessing CareProximal cancersMedian OSIV diseaseGrowth characteristics of HCT116 xenografts lacking asparagine synthetase vary according to sex
Aladelokun O, Lu L, Zheng J, Yan H, Jain A, Gibson J, Khan S, Johnson C. Growth characteristics of HCT116 xenografts lacking asparagine synthetase vary according to sex. Human Genomics 2024, 18: 67. PMID: 38886847, PMCID: PMC11184737, DOI: 10.1186/s40246-024-00635-3.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAspartate-Ammonia LigaseCarbon-Nitrogen Ligases with Glutamine as Amide-N-DonorCell ProliferationColorectal NeoplasmsFemaleGene Expression Regulation, NeoplasticHCT116 CellsHeterograftsHumansMaleMiceReceptors, EstrogenReceptors, G-Protein-CoupledSex FactorsXenograft Model Antitumor AssaysConceptsFemale tumor-bearing miceFemale CRC patientsTumor-bearing miceCRC patientsTumor growthInferior survivalAssociated with inferior survivalMetabolic reprogrammingG protein-coupled estrogen receptorTriggering metabolic reprogrammingSustained tumor growthSuppressed tumor growthExpression of asparagine synthetaseCancer cell linesBackgroundSex-related differencesSurvival improvementImpact of sexFemale miceEstrogen receptorCancer growthTranslational relevanceRewiring of metabolic pathwaysCancer burdenMetabolic pathwaysAsparagine synthetase
2023
Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations
Yan H, Talty R, Jain A, Cai Y, Zheng J, Shen X, Muca E, Paty P, Bosenberg M, Khan S, Johnson C. Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations. Redox Biology 2023, 62: 102699. PMID: 37086630, PMCID: PMC10172914, DOI: 10.1016/j.redox.2023.102699.Peer-Reviewed Original ResearchConceptsKRAS mutant tumorsMale CRC patientsCRC patientsMale patientsKRAS mutationsMutant tumorsOverall survivalMale colorectal cancer patientsKRAS wild-type tumorsAberrant tumor metabolismColorectal cancer patientsCRC patient cohortsColorectal cancer casesFerroptosis-related genesWild-type tumorsNovel potential avenuesNormal colon tissuesPoor OSKRAS statusAdverse outcomesCRC cellsPatient cohortCancer patientsType tumorsCancer cases
2022
Bile acid distributions, sex-specificity, and prognosis in colorectal cancer
Cai Y, Shen X, Lu L, Yan H, Huang H, Gaule P, Muca E, Theriot CM, Rattray Z, Rattray NJW, Lu J, Ahuja N, Zhang Y, Paty PB, Khan SA, Johnson CH. Bile acid distributions, sex-specificity, and prognosis in colorectal cancer. Biology Of Sex Differences 2022, 13: 61. PMID: 36274154, PMCID: PMC9590160, DOI: 10.1186/s13293-022-00473-9.Peer-Reviewed Original ResearchConceptsLeft-sided colon tumorsRight-sided colon tumorsColon cancer patientsColorectal cancerTumor locationBile acidsColon tumorsCancer patientsQuantitative immunofluorescencePrimary tumor locationImmune regulatory cellsRecurrence-free survivalBile acid metabolismSecondary bile acidsBile acid distributionBile acid analysisBackgroundBile acidsOverall survivalRegulatory cellsCRC patientsMale patientsPatient sexImmune cellsPatient prognosisImmune responseAsparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review
Shen X, Jain A, Aladelokun O, Yan H, Gilbride A, Ferrucci LM, Lu L, Khan SA, Johnson CH. Asparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review. Frontiers In Molecular Biosciences 2022, 9: 958666. PMID: 36090030, PMCID: PMC9453556, DOI: 10.3389/fmolb.2022.958666.Peer-Reviewed Original ResearchColorectal cancerCRC patientsNarrative reviewSex steroid hormone estrogenFemale CRC patientsAnti-tumor effectsPI3K/Akt/Sex-related influencesSex-related factorsAsparagine synthetase expressionSex-specific factorsClinical outcomesTumor burdenCRC progressionPoor prognosisHormone estrogenEstrogen receptorSOX12 expressionRole of sexTherapeutic useAkt/Cancer cellsSynthetase expressionL-asparaginasePatientsRefining colorectal cancer classification and clinical stratification through a single-cell atlas
Khaliq A, Erdogan C, Kurt Z, Turgut S, Grunvald M, Rand T, Khare S, Borgia J, Hayden D, Pappas S, Govekar H, Kam A, Reiser J, Turaga K, Radovich M, Zang Y, Qiu Y, Liu Y, Fishel M, Turk A, Gupta V, Al-Sabti R, Subramanian J, Kuzel T, Sadanandam A, Waldron L, Hussain A, Saleem M, El-Rayes B, Salahudeen A, Masood A. Refining colorectal cancer classification and clinical stratification through a single-cell atlas. Genome Biology 2022, 23: 113. PMID: 35538548, PMCID: PMC9092724, DOI: 10.1186/s13059-022-02677-z.Peer-Reviewed Original ResearchConceptsConsensus molecular subtypesTumor microenvironmentAssociated with immunotherapy resistanceCAF subtypesImmune checkpoint inhibitorsHuman CRC samplesIndependent external cohortMechanism of tumorsMSI-HContribution to pathogenesisResultsTumor cellsCheckpoint inhibitorsImmunotherapy resistanceImmunotherapy responseEpithelial levelClinicopathological characteristicsMolecular subtypesClinical stratificationCRC patientsMicroenvironmental cellsPatient prognosisPoor outcomeMSI-H CRCsBackgroundColorectal cancerColorectal cancer classificationDownregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer
Li Y, Gan Y, Liu J, Li J, Zhou Z, Tian R, Sun R, Liu J, Xiao Q, Li Y, Lu P, Peng Y, Peng Y, Shu G, Yin G. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduction And Targeted Therapy 2022, 7: 87. PMID: 35351858, PMCID: PMC8964798, DOI: 10.1038/s41392-022-00902-6.Peer-Reviewed Original ResearchConceptsOxaliplatin resistanceColorectal cancerTumor growthMEIS1 expressionCell sensitivity to oxaliplatinPreventing DNA damage repairCombination of oxaliplatinSurvival of CRC patientsTreatment of colorectal cancerSensitivity to oxaliplatinEZH2 inhibitor GSK126Suppressed tumor growthReverse oxaliplatin resistanceFrontline treatmentAcquired ResistanceCRC patientsInhibitor GSK126OxaliplatinFEN1 expressionTherapeutic strategiesDNA damage repairELFN1-AS1Cell survivalMeis1PatientsAsparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study
Shen X, Cai Y, Lu L, Huang H, Yan H, Paty PB, Muca E, Ahuja N, Zhang Y, Johnson CH, Khan SA. Asparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study. Metabolites 2022, 12: 164. PMID: 35208238, PMCID: PMC8875032, DOI: 10.3390/metabo12020164.Peer-Reviewed Original ResearchRecurrence-free survivalOverall survivalColorectal cancer prognosisPoor overall survivalPrimary tumor tissuesTumor metabolomeUnique metabolite profilesCohort studyCRC patientsCRC treatmentFemale patientsPoor prognosisColorectal cancerPrognostic disadvantagePatient outcomesPoor survivalSurgical colectomySex-specific differencesCox proportionalEleven metabolitesUntargeted metabolomics analysisCancer prognosisStage ITumor tissueSignificant sex differences
2021
Molecular Mechanisms of Alcohol-Induced Colorectal Carcinogenesis
Johnson CH, Golla JP, Dioletis E, Singh S, Ishii M, Charkoftaki G, Thompson DC, Vasiliou V. Molecular Mechanisms of Alcohol-Induced Colorectal Carcinogenesis. Cancers 2021, 13: 4404. PMID: 34503214, PMCID: PMC8431530, DOI: 10.3390/cancers13174404.Peer-Reviewed Original ResearchColorectal cancerColorectal carcinogenesisChronic alcohol consumptionMost CRC patientsSporadic colorectal cancerGenetic risk factorsEffects of alcoholBacterial translocationCRC patientsFamilial cancer syndromeIntestinal permeabilityRisk factorsAlcohol consumptionCancer syndromesCRC modelMechanisms of alcoholAlcohol metabolitesGermline mutationsOne-carbon metabolismExact mechanismReactive oxygen speciesSporadic cancersCarcinogenesisImmunosuppressionCancerTumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived From Cancer Signaling in Colorectal Cancer
Penny SA, Abelin JG, Malaker SA, Myers PT, Saeed AZ, Steadman LG, Bai DL, Ward ST, Shabanowitz J, Hunt DF, Cobbold M. Tumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived From Cancer Signaling in Colorectal Cancer. Frontiers In Immunology 2021, 12: 723566. PMID: 34504498, PMCID: PMC8421858, DOI: 10.3389/fimmu.2021.723566.Peer-Reviewed Original ResearchConceptsT cell responsesColorectal cancerCRC patientsPatient tumorsTumor antigensCell responsesPeripheral T cell responsesCytotoxic T-cell infiltrationFuture immunotherapeutic strategiesCRC liver metastasesNovel immunotherapeutic targetT cell infiltrationTumor-infiltrating lymphocytesTumor-specific antigensPrimary CRC tumorsCRC cell linesKey prognostic indicatorMarker of malignancyCRC patient tumorsMultifunctional CD8Immunotherapeutic strategiesLiver metastasesInfiltrating lymphocytesCytokine responsesSame HLAExome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer
Fernández-Rozadilla C, Álvarez-Barona M, Quintana I, López-Novo A, Amigo J, Cameselle-Teijeiro J, Roman E, Gonzalez D, Llor X, Bujanda L, Bessa X, Jover R, Balaguer F, Castells A, Castellví-Bel S, Capellá G, Carracedo A, Valle L, Ruiz-Ponte C. Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer. Scientific Reports 2021, 11: 11135. PMID: 34045552, PMCID: PMC8159954, DOI: 10.1038/s41598-021-90590-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultColorectal NeoplasmsDNA HelicasesDNA Repair EnzymesDNA-Binding ProteinsExomeExome SequencingFemaleGene Expression Regulation, NeoplasticGenetic HeterogeneityGenetic Predisposition to DiseaseHumansMaleMethyltransferasesMiddle AgedPoly-ADP-Ribose Binding ProteinsProtein Tyrosine Phosphatase, Non-Receptor Type 13ConceptsEarly-onset CRC patientsColorectal cancerCRC patientsEarly-onset patientsGenetic variantsPotential risk allelesCRC onsetYoungest caseCRC developmentIndependent patientsPatientsTruncating variantsRisk allelesExome sequencingNovel genetic variantsRobust studiesTDG geneDisease developmentCandidate variantsCancerMolecular heterogeneityDiseaseComplex diseasesGenetic heterogeneityHigh-impact variantsHsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer
Klemke L, De Oliveira T, Witt D, Winkler N, Bohnenberger H, Bucala R, Conradi LC, Schulz-Heddergott R. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death & Disease 2021, 12: 155. PMID: 33542244, PMCID: PMC7862487, DOI: 10.1038/s41419-021-03426-z.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenic ProteinsAnimalsAntigens, Differentiation, B-LymphocyteAntineoplastic AgentsColitis-Associated NeoplasmsDisease Models, AnimalFemaleHCT116 CellsHEK293 CellsHistocompatibility Antigens Class IIHSP90 Heat-Shock ProteinsHumansInflammation MediatorsIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMice, Inbred C57BLMice, KnockoutNeovascularization, PathologicOrganoidsProtein StabilitySignal TransductionTumor BurdenTumor-Associated MacrophagesConceptsMacrophage migration inhibitory factorMIF levelsMacrophage recruitmentAction of MIFColitis-associated colorectal cancer (CAC) mouse modelTumor growthTumor progressionFunction of MIFColorectal cancer mouse modelHigher MIF levelsHost inflammatory pathwaysTumor-specific functionsEpithelial cellsShorter overall survivalCRC tumor progressionClinical correlation studiesMigration inhibitory factorCRC tumor growthCancer mouse modelWild-type organoidsTumor epithelial cellsHSP90 inhibitor treatmentCD74 expressionOverall survivalCRC patientsImmune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
Liu J, Huang X, Liu H, Wei C, Ru H, Qin H, Lai H, Meng Y, Wu G, Xie W, Mo X, Johnson CH, Zhang Y, Tang W. Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients. Journal Of Translational Medicine 2021, 19: 27. PMID: 33413474, PMCID: PMC7789428, DOI: 10.1186/s12967-020-02638-9.Peer-Reviewed Original ResearchConceptsKRAS mutant CRC patientsTumor-infiltrating immune cellsKRAS wild-type CRC patientsCD4 memory T cellsCRC patientsMemory T cellsColorectal cancerT cellsImmune pathwaysImmune cellsMacrophage M1Hypersensitive C-reactive proteinKRAS-mutant colorectal cancerCases of CRCKRAS mutantPrognostic immune-related genesImmune risk modelColorectal cancer patientsRegulatory T cellsC-reactive proteinTumor immune microenvironmentDistinct clinical outcomesT cell receptorImmune-related genesConclusionsKRAS mutation
2020
Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies
Vyas M, Firat C, Hechtman J, Weiser M, Yaeger R, Vanderbilt C, Benhamida J, Keshinro A, Zhang L, Ntiamoah P, Gonzalez M, Andrade R, El Dika I, Markowitz A, Smith J, Garcia-Aguilar J, Vakiani E, Klimstra D, Stadler Z, Shia J. Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. Familial Cancer 2020, 20: 201-213. PMID: 33033905, PMCID: PMC8032798, DOI: 10.1007/s10689-020-00210-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinomaCohort StudiesColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisDNA Mismatch RepairDNA-Binding ProteinsFemaleGastrointestinal NeoplasmsGerm-Line MutationHumansMaleMicrosatellite InstabilityMiddle AgedMismatch Repair Endonuclease PMS2Neoplasms, Multiple PrimaryNeoplasms, Second PrimaryConceptsPolymerase proofreading-associated polyposisFamilial adenomatous polyposisLynch syndromeColorectal cancerMismatch repair testingMismatch repair genesMismatch repairTumor DNA mismatch repairMMR-deficient carcinomasTreatment decision-makingAdenomatous polyposisLS detectionMismatch repair proteinsDNA mismatch repairSynchronous/metachronous tumorsHereditary syndromesGermline mutationsPrimary colorectal cancerPolyposisCRC patientsMismatch repair protein statusMMR-deficient cancersCancerEffective strategyDecision-makingRisk of Cancer in Family Members of Patients with Lynch-Like Syndrome
Picó MD, Sánchez-Heras AB, Castillejo A, Giner-Calabuig M, Alustiza M, Sánchez A, Moreira L, Pellise M, Castells A, Llort G, Yagüe C, Ramon y Cajal T, Gisbert-Beamud A, Cubiella J, Rivas L, Herraiz M, Garau C, Salces I, Carrillo-Palau M, Bujanda L, López-Fernández A, Alvarez-Urturi C, López MJ, Alenda C, Zapater P, Lacueva FJ, Balaguer F, Soto JL, Murcia Ó, Jover R. Risk of Cancer in Family Members of Patients with Lynch-Like Syndrome. Cancers 2020, 12: 2225. PMID: 32784934, PMCID: PMC7466118, DOI: 10.3390/cancers12082225.Peer-Reviewed Original ResearchFDRs of patientsLynch-like syndromeFirst-degree relativesStandardized incidence ratiosColorectal cancerLynch syndromeLLS patientsRisk of CRCHereditary colorectal cancerPathogenic mutationsGermline pathogenic mutationsRisk of cancerLoss of MLH1Mismatch repair deficiencyCRC patientsIncidence ratiosLS patientsImmunohistochemical lossCommon causeHigh incidencePatientsNeoplasmsSyndromeRepair deficiencyRiskTumor Tissue-Specific Biomarkers of Colorectal Cancer by Anatomic Location and Stage
Cai Y, Rattray NJW, Zhang Q, Mironova V, Santos-Neto A, Muca E, Vollmar AKR, Hsu KS, Rattray Z, Cross JR, Zhang Y, Paty PB, Khan SA, Johnson CH. Tumor Tissue-Specific Biomarkers of Colorectal Cancer by Anatomic Location and Stage. Metabolites 2020, 10: 257. PMID: 32575361, PMCID: PMC7345993, DOI: 10.3390/metabo10060257.Peer-Reviewed Original ResearchColorectal cancerAnatomic locationTissue-specific biomarkersOrthogonal partial least squares discriminant analysisBlood samplesMetabolite biomarkersTumor tissueRight-sided colon cancerPatient blood samplesCRC patientsStudy cohortScreening regimensIndependent cohortUntargeted metabolomics analysisStage IColon cancerDisease influenceMetabolic consequencesDiscriminatory biomarkersNormal colonMetabolic signaturesPre-validation phaseBiomarker studiesBiomarkersCancerMicrosatellite instability and KRAS mutation in stage 4 CRC: Prevalence, geographic discrepancies and outcomes from the National Cancer Database.
Uhlig J, Cecchini M, Stein S, Lacy J, Kim K. Microsatellite instability and KRAS mutation in stage 4 CRC: Prevalence, geographic discrepancies and outcomes from the National Cancer Database. Journal Of Clinical Oncology 2020, 38: e16052-e16052. DOI: 10.1200/jco.2020.38.15_suppl.e16052.Peer-Reviewed Original ResearchNational Cancer DatabaseOverall survivalKRAS statusKRAS mutationsMicrosatellite instabilityMicrosatellite statusCancer DatabaseCRC siteStage IV colorectal adenocarcinomaStage IV CRC patientsUnited States National Cancer DatabaseCox proportional hazards modelStage IV CRCKRAS mutation rateRight-sided CRCProportional hazards modelDistinct prognostic profilesStatistical interaction testsKRAS wildtypePatient demographicsCRC patientsMetastatic burdenCRC treatmentMultivariable analysisPrognostic profileSex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype
Cai Y, Rattray NJW, Zhang Q, Mironova V, Santos-Neto A, Hsu KS, Rattray Z, Cross JR, Zhang Y, Paty PB, Khan SA, Johnson CH. Sex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype. Scientific Reports 2020, 10: 4905. PMID: 32184446, PMCID: PMC7078199, DOI: 10.1038/s41598-020-61851-0.Peer-Reviewed Original ResearchConceptsRight-sided colon cancerColorectal cancerCRC patientsColon cancer metabolismPoor clinical outcomePatient colon tumorsAsparagine synthetase expressionNovel subphenotypesClinical outcomesAmino acid uptakePoor survivalLower incidenceAnatomic locationHigh incidenceTherapeutic targetColon cancerCancer Genomic AtlasClinical importanceColon tumorsTumor progressionAberrant metabolismNormal tissuesPatientsSubphenotypesAcid uptake
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply